People on HIV drugs have ‘substantial’ Alzheimer’s protection: study

People taking drugs for HIV and hepatitis B are less likely to develop Alzheimer’s disease, according to a new study. UVA Health investigators now would like clinical trials to examine the potential of the HIV medications as a means to prevent Alzheimer’s disease.

REINFORCE Resource Guide

This Resource Guide was developed as part of the HealthHIV REINFORCE initiative supporting five healthcare organizations to increase their retention and re-engagement in HIV care rates. These sites, situated around the country, ranged from large multi-site hospitals and health centers to small community-based organizations.

Inflamm-aging: Effects of Chronic Inflammation with HIV

Advances in Antiretroviral therapy (ART) allow people with HIV to live longer with fewer medications. Join us as Dr. Peter Hunt details the connection between chronic inflammation and HIV infection and discusses care considerations and emerging research.

Differentiated Service Delivery Models Have Comparable Effectiveness to Standard of Care in HIV

Differentiated service delivery (DSD) models were able to provide comparable effectiveness in treating people with HIV as the standard of care (SoC) when it came to maintaining care and viral suppression, according to a review published in Reviews in Medical Virology.

What is the HIV Care Continuum?

This resource from HIV.gov describes the HIV care continuum, a public health model that outlines the steps or stages that people with HIV go through from diagnosis to achieving and maintaining viral suppression through care and treatment.

After ARVs

Has the dawn of HIV therapeutic vaccines arrived at AIDS 2022?

Monocytes in HIV and SIV Infection and Aging: Implications for Inflamm-Aging and Accelerated Aging

With ART and the extended lifespan of PLWH, HIV comorbidities also include aging—most likely due to accelerated aging—as well as cardiovascular, neurocognitive disorders, lung and kidney disease, and malignancies. The broad evidence suggests that HIV with ART is associated with accentuated aging and that the age-related comorbidities occur earlier, due in part to chronic immune activation, co-infections, and possibly the effects of ART alone.

Part B: AIDS Drug Assistance Program (ADAP)

Senotherapeutics for HIV and aging

Senescence is a hallmark of aging-related diseases that is characterized by stable cell cycle arrest and chronic inflammation. Chronic HIV-1 infection predisposes patients to aging-related illnesses and is similarly marked by a senescence-like phenotype. A better understanding of the role of HIV-1 in aging will inform the development of therapeutics aimed at eliminating senescent cells that drive accelerated physiologic aging.

Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America

To optimize care engagement, medication adherence, and viral suppression, all people with HIV should be provided timely access to care, and HIV care sites should make the effort to provide care in a way that is linguistically and culturally appropriate. HIV care sites should implement programs that incorporate evidence-based programs to improve HIV care engagement and viral suppression.

Maintaining HIV care during the COVID-19 pandemic

Weak healthcare systems have been exposed during the COVID-19 pandemic and challenges have arisen in regard to maintaining HIV care continuum during the COVID-19 pandemic. Particular efforts must focus on ensuring this care to avoid disruption of routine HIV services.

Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study

Co-morbidities and multi-morbidities are extremely prevalent in people living with HIV. More than 50% of PLHW were multi-morbid and about 30% had three or more comorbidities. Those living with HIV are much more at risk of dying or living with more than one disease.